00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
23:07 , Mar 25, 2019 |  BC Extra  |  Financial News

Biogen announces $5B stock buyback on heels of Alzheimer’s hit

For the second time in a year, Biogen has announced a share repurchase program on the heels of bad news from an Alzheimer's candidate. This time, the big biotech has authorized the repurchase of $5...
04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
21:44 , Mar 22, 2019 |  BC Extra  |  Clinical News

After aducanumab failure, Eisai to test another anti-amyloid mAb

With the announcement that Eisai plans to start yet another Phase III trial of an anti-amyloid candidate, Alzheimer's disease researcher Rudolph Tanzi told BioCentury he wouldn't enroll any more AD patients in trials of therapies...
00:43 , Mar 22, 2019 |  BioCentury  |  Finance

Biogen's lead balloon

Biogen took a 29% haircut to $226.88 on Thursday following its decision to discontinue the Phase III ENGAGE and EMERGE trials of aducanumab for Alzheimer’s disease. The company's stock price has been dragged down 48%...
12:30 , Mar 21, 2019 |  BC Extra  |  Clinical News

Biogen, Eisai discontinuing aducanumab studies in AD

Biogen and Eisai said aducanumab is unlikely to meet the primary endpoints of two Phase III trials to treat early Alzheimer's disease, joining a long list of failed mAbs against β amyloid and putting more...
20:09 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Syncona leads CHF35M A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round on Feb. 26 to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC)...
19:28 , Feb 26, 2019 |  BC Extra  |  Financial News

Syncona leads CHF35 million A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round Tuesday to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC) is leading...
23:05 , Feb 1, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 15 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 3Q; (B) Fiscal 2Q; (C) During trading hours in Europe; premarket on U.S. exchange Company Date...
01:11 , Feb 1, 2019 |  BC Week In Review  |  Clinical News

Roche stops crenezumab trials in early Alzheimer's for futility

The β amyloid hypothesis for treating Alzheimer's disease suffered another setback on Jan. 30 after Roche (SIX:ROG; OTCQX:RHHBY) discontinued a pair of Phase III trials of crenezumab (RG7412) to treat early AD. Roche's Genentech Inc....